NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAII)

Filing Type: Form 10-Q (Quarterly Report)

Reporting Period: Three months ended September 30, 2024

Business Overview: NAII operates in two primary segments: private-label contract manufacturing of nutritional supplements and patent/trademark licensing (primarily beta-alanine ingredients under the CarnoSyn® brand). The company is a smaller reporting company and non-accelerated filer.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 2% year-over-year. Private-label contract manufacturing sales dropped 5% due to reduced orders from a major customer, partially offset by growth in other accounts. Conversely, patent and trademark licensing revenue surged 42% to $2.52 million, driven by decreased volume rebates and increased orders.
• Margin Compression: Gross profit margin contracted from 9.2% to 6.8%. This was primarily caused by an unfavorable sales mix shift toward lower-margin contract manufacturing and increased manufacturing costs (labor, supplies, rent, and freight).
• Increased Operating Loss: Operating loss widened significantly to $1.84 million from $0.54 million. Selling, general, and administrative (SG&A) expenses rose 11% due to higher compensation and legal fees.
• Cash Flow Deterioration: Operating cash flow swung from a positive $4.5 million in the prior year to a negative $3.4 million usage. This was driven by inventory build-up ($1.7 million cash use) and reduced accounts payable collections timing.
• Foreign Exchange Impact: Foreign exchange losses increased to $0.43 million from $0.28 million, contributing to other expenses.

Guidance, Outlook, and Risks

• Financial Covenant Breach: As of September 30, 2024, the company was not in compliance with financial covenants related to net income requirements under its credit facility with Wells Fargo. Management anticipates non-compliance will continue for the next two quarters of fiscal 2025.
• Outlook: Management expects a net loss in the first half of fiscal 2025, net income in the second half, and an overall net loss for the full fiscal year 2025, despite a forecasted significant increase in sales compared to fiscal 2024.
• Debt Negotiations: The company is currently negotiating a revised credit facility or waiver with Wells Fargo. The lender has agreed not to exercise default options while negotiations are ongoing but reserves all rights.
• Product Strategy: The company is focusing on the commercialization of new products, specifically TriBsyn™ (a carnosine booster) and SR CarnoSyn®, to penetrate the Wellness and Healthy Aging markets.
• Risk Factors: Significant risks include customer concentration (top customer represents 37% of sales), reliance on limited raw material suppliers, and geopolitical instability (Israel-Hamas/Hezbollah conflict) affecting supply chains and raw material sourcing.

Investor Verification Checklist

• Credit Facility Status: Verify the outcome of negotiations with Wells Fargo regarding the covenant waiver or facility restructuring, as failure to secure terms could trigger a default.
• Liquidity Runway: Confirm that the $10.2 million cash balance and remaining $7.1 million borrowing capacity are sufficient to fund operations through the anticipated loss period in H1 2025.
• Customer Concentration: Monitor the stability of the top customer (37% of sales) and the impact of their order reductions on future revenue guidance.
• Inventory Levels: Assess the $25.9 million inventory balance against sales trends to ensure the recent cash outflow for inventory build-up does not lead to obsolescence or write-downs.
• FX Hedging Effectiveness: Review the impact of foreign exchange volatility on future margins, given the significant unrealized losses on derivative instruments recorded in Other Comprehensive Loss.